Summit Therapeutics PLC (LON:SUMM)

Summit Therapeutics PLC (LON:SUMM)

Share Price
23.75 p
0 (0.00 %)
Market Cap
£38.12 m
Proactive Investors - Run By Investors For Investors

Summit Therapeutics PLC

Summit Therapeutics is a leader in antibiotic innovation. Summit’s new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. The company is currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and is using its proprietary...

Market: AIM:SUMM
52-week High/Low: 202.49p / 9.50p
Sector: Pharma & Biotech
Market Cap: £38.12 m
col 3
col 4
col 5
col 6

Summit Therapeutics PLC RNS Announcements

Date Epic Announcement
20/06/2019 SUMM Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
19/06/2019 SUMM Result of AGM
18/06/2019 SUMM Increased BARDA Award and Option Exercise
12/06/2019 SUMM Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
05/06/2019 SUMM Notice of First Quarter Results
14/05/2019 SUMM UK Annual Report and Notice of AGM
29/04/2019 SUMM Block Listing Interim Review
24/04/2019 SUMM Exercise of Restricted Stock Units
15/04/2019 SUMM Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
03/04/2019 SUMM Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
02/04/2019 SUMM Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
29/03/2019 SUMM Award of Share Options
29/03/2019 SUMM Filing of Annual Report on Form 20-F
27/03/2019 SUMM Final Results
25/03/2019 SUMM Notice of Results
18/03/2019 SUMM Summit Therapeutics to Present at Upcoming Conferences
14/03/2019 SUMM Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
25/02/2019 SUMM Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
13/02/2019 SUMM Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
08/02/2019 SUMM Summit Therapeutics to Present at the BIO CEO & Investor Conference
15/01/2019 SUMM Holding(s) in Company
14/01/2019 SUMM Award of Restricted Stock Units
10/01/2019 SUMM Holding(s) in Company
10/01/2019 SUMM Holding(s) in Company
10/01/2019 SUMM Completion of $25 million Subscription
09/01/2019 SUMM Holding(s) in Company
08/01/2019 SUMM Update on Admission
04/01/2019 SUMM Result of General Meeting
02/01/2019 SUMM Holding(s) in Company
18/12/2018 SUMM Holding(s) in Company

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use